Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 25, 2024 12:43pm

73 Views

Post# 36007453

RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

December 07, 2023 - - Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor
- Data highlights the association between the expansion of existing TILs in the blood and decreased tumor size
- Results affirm pelareorep's role as an immunotherapy

https://www.newswire.ca/news-releases/oncolytics-biotech-r-and-solti-present-positive-translational-data-at-sabcs-832342590.html